会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Indole derivatives
    • INDOLE DORIVATIVES
    • US5066660A
    • 1991-11-19
    • US570513
    • 1990-08-21
    • Alexander W. OxfordIan H. CoatesDarko Butina
    • Alexander W. OxfordIan H. CoatesDarko Butina
    • A61K31/4427A61K31/445A61P25/04A61P25/06C07D401/04
    • C07D401/04
    • Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents H or C.sub.1-6 alkyl;R.sub.2 represents H, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phen(C.sub.1-3)alkyl in which the phenyl ring is optionally substituted by halogen, C.sub.1-4 alkoxy, hydroxy or C.sub.1-3 alkyl;R.sub.3 represents H, C.sub.1-3 alkyl, --CO.sub.2 R.sub.5, --COR.sub.5, --COCO.sub.2 R.sub.5 or --CONHR.sub.5 whereR.sub.5 represents H, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-4 alkenyl, aryl or ar(C.sub.1-4)alkyl in which the aryl group is optionally substituted by halogen, C.sub.1-4 alkoxy, C.sub.1-4 alkyl or hydroxy) (provided that where R.sub.3 represents --CO.sub.2 R.sub.5, R.sub.5 is other than H);R.sub.4 represents H, C.sub.1-3 alkyl, C.sub.3-6 alkenyl, phenyl or phen (C.sub.1-3)alkyl;A-B represents CH--CH.sub.2 --or C.dbd.CH--D represents --CO-- or --SO.sub.2 --n represents 0, 1-5;provided that when D represents --SO.sub.2, n is 2, R.sub.3 represents H and R.sub.4 represents H or C.sub.1-3 alkyl, R.sub.2 is other than H or C.sub.1-6 alkyl; and pharmaceutically acceptable salts and solvates (for example hydrates) thereof.The compounds are indicated as useful for the treatment of migraine, cluster headache, chronic paroxysmal hemicrania and headache associated with vascular disorders.Processes and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.
    • 2. 发明申请
    • Method and system for providing consumer opinions to companies
    • 向公司提供消费者意见的方法和系统
    • US20080013700A1
    • 2008-01-17
    • US11784814
    • 2007-04-10
    • Darko Butina
    • Darko Butina
    • H04M11/00
    • H04L51/36G06Q30/02
    • Method and system for accepting, handling and distributing opinions and feedback to any entity, company or institution from any customer or user. Opinions can be sent through various communication channels such as mobile phones, SMS messaging systems, other mobile devices, PC (internet), phones and the like. The system enables two-way communication between companies and users while users remain anonymous towards companies. Opinions are handled in accordance with locations for which they are sent for, in accordance with user information and in accordance with communication channel they were sent through. Users can send their opinions in the same manner for all companies and institutions, which means that the system presents one-point stop for all opinions users want to communicate to various companies. Two-way communication which is possible with the use of the system also gives companies additional value for their customer relationship management.
    • 从任何客户或用户接受,处理和分发意见和反馈给任何实体,公司或机构的方法和系统。 意见可以通过诸如移动电话,SMS消息系统,其他移动设备,PC(互联网),电话等各种通信信道发送。 该系统使公司和用户之间进行双向通信,而用户对公司保持匿名。 根据用户信息并根据其发送的通信渠道,根据发送位置处理意见。 用户可以以同样的方式向所有公司和机构发表意见,这意味着系统对用户希望与各公司沟通的所有意见都提出一站式的停留。 使用系统可能的双向通信也为公司提供了客户关系管理的额外价值。
    • 3. 发明授权
    • 5-Substituted-3-aminoalkyl indole derivatives
    • 5-取代的3-氨基烷基吲哚衍生物
    • US4894387A
    • 1990-01-16
    • US030235
    • 1987-03-26
    • Darko ButinaMichael D. DowleIan H. Coates
    • Darko ButinaMichael D. DowleIan H. Coates
    • C07D209/14A61K31/40A61K31/403A61K31/404A61P9/00A61P25/04C07C67/00C07C301/00C07C311/35C07D209/16C07D209/18
    • C07D209/18C07D209/16
    • Compounds are disclosed of the general formula (I) ##STR1## wherein R.sub.1 represents halogen, alkyl, alkoxy or hydroxyl, or a group NR.sub.a R.sub.b or CON.sub.a R.sub.b, where R.sub.a and R.sub.b are hydrogen, alkyl or alkenyl or with the nitrogen atom form a saturated monocyclic 5 to 7-membered ring;R.sub.2 represents hydrogen or alkyl;R.sub.3 and R.sub.4 represent hydrogen, C.sub.1-3 alkyl or propenyl or R.sub.3 and R.sub.4 together form an aralkylidene group; Alk represents a C.sub.2-3 alkylene chain;n and m, are integers of 1 to 4 or n is zero, and their physiologically acceptable salts and solvates.The compounds are described as useful in treating pain originating from dilatation of the cranial vasculature in particular migraine and cluster headache and can be formulated in conventional manner as pharmaceutical compositions with carriers or excipients for administration by any convenient route.
    • 公开了通式(I)的化合物其中R 1表示卤素,烷基,烷氧基或羟基,或NRaRb或CONaRb基团,其中R a和R b是氢,烷基或链烯基或氮原子形式 饱和单环5至7元环; R2代表氢或烷基; R3和R4代表氢,C1-3烷基或丙烯基或R3和R4一起形成亚烷基; Alk表示C2-3亚烷基链; n和m是1〜4的整数或n为0的整数,以及它们的生理上可接受的盐和溶剂合物。 描述了这些化合物可用于治疗源于颅血管扩张的疼痛,特别是偏头痛和丛集性头痛,并且可以以常规方式配制成具有载体或赋形剂的药物组合物,通过任何方便的途径给药。
    • 4. 发明授权
    • 5-Aminosulphoryl substituted indole derivatives
    • 5-氨基磺酰基取代的吲哚衍生物
    • US4876267A
    • 1989-10-24
    • US66498
    • 1987-06-26
    • Darko ButinaMichael D. DowleDavid E. BaysColin F. Webb
    • Darko ButinaMichael D. DowleDavid E. BaysColin F. Webb
    • A61K31/40A61K31/403A61K31/404A61P25/04A61P25/06C07D209/16
    • C07D209/16
    • Indole derivatives are disclosed of the formula (I): ##STR1## wherein R.sub.1 represents H, or C.sub.1-6 alkyl or C.sub.3-6 Alkenyl;R.sub.2 represents a H, C.sub.1-3 alkyl, C.sub.3-6 alkenyl or C.sub.5-7 cycloalkyl, or a phenyl or phen(C.sub.1-4)alkyl group in which the phenyl ring is optionally substituted by halogen or C.sub.1-3 alkyl, C.sub.1-3 alkoxy or hydroxyl, or by a group NR.sup.a R.sup.b, or CONR.sup.a R.sup.b, wherein R.sup.a and R.sup.b each independently represents H or C.sub.1-3 alkyl;R.sub.3 and R.sub.4, each independently represents H or C.sub.1-3 alkyl or 2-propenyl;and physiologically acceptable salts and solvates (e.g. hydrates) thereof.The compounds have potent and selective vasoconstrictor activity and are indicated as useful for the treatment of migraine. The compounds may be formulated as pharmaceutical compositions with pharmaceutically acceptable carriers or excipients for administration by any suitable means. Various methods for the preparation of the compounds are disclosed.
    • 公开了式(I)的吲哚衍生物:其中R 1表示H或C 1-6烷基或C 3-6烯基的(I) R 2表示H,C 1-3烷基,C 3-6烯基或C 5-7环烷​​基,或苯基或苯基(C 1-4)烷基,其中苯环任选被卤素或C 1-3烷基取代,C1- 3烷氧基或羟基,或NRaRb或CONRaRb基团,其中Ra和Rb各自独立地表示H或C1-3烷基; R 3和R 4各自独立地表示H或C 1-3烷基或2-丙烯基; 和其生理上可接受的盐和溶剂合物(例如水合物)。 这些化合物具有有效和选择性的血管收缩剂活性,并被用于治疗偏头痛。 这些化合物可以配制成具有药学上可接受的载体或赋形剂的药物组合物,用于通过任何合适的方式给药。 公开了制备化合物的各种方法。